Related references
Note: Only part of the references are listed.Clinical outcomes following hematopoietic stem cell transplantation for the treatment of mucopolysaccharidosis VI
Sean Turbeville et al.
MOLECULAR GENETICS AND METABOLISM (2011)
Echocardiographic study of paediatric patients with mucopolysaccharidosis
Gabriela N. Leal et al.
CARDIOLOGY IN THE YOUNG (2010)
Enzyme replacement therapy for mucopolysaccharidosis VI from 8 weeks of age-a sibling control study
J. J. McGill et al.
CLINICAL GENETICS (2010)
Enzyme replacement therapy for mucopolysaccharidosis VI: evaluation of long-term pulmonary function in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase
Paul Harmatz et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2010)
Mucopolysaccharidosis VI
Vassili Valayannopoulos et al.
ORPHANET JOURNAL OF RARE DISEASES (2010)
The natural course and the impact of therapies of cardiac involvement in the mucopolysaccharidoses
Vlasta Fesslova et al.
CARDIOLOGY IN THE YOUNG (2009)
Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data
A. Mehta et al.
LANCET (2009)
Long-term Efficacy and Safety of Laronidase in the Treatment of Mucopolysaccharidosis I
Lorne A. Clarke et al.
PEDIATRICS (2009)
Mucopolysaccharidoses in the Scandinavian countries: incidence and prevalence
Gunilla Malm et al.
ACTA PAEDIATRICA (2008)
Initial report from the Hunter Outcome Survey
J. Edmond Wraith et al.
GENETICS IN MEDICINE (2008)
Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI:: Final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase
Paul Harmatz et al.
MOLECULAR GENETICS AND METABOLISM (2008)
Successful management of difficult infusion-associated reactions in a young patient with mucopolysaccharidosis type VI receiving recombinant human arylsulfatase B (galsulfase [Naglazyme])
Katherine H. Kim et al.
PEDIATRICS (2008)
Mutational analysis of 105 mucopolysaccharidosis type VI patients
Litsa Karageorgos et al.
HUMAN MUTATION (2007)
Brain MRI in mucopolysaccharidosis - Effect of aging and correlation with biochemical findings
L. Vedolin et al.
NEUROLOGY (2007)
Management guidelines for mucopolysaccharidosis VI
Roberto Giugliani et al.
PEDIATRICS (2007)
Standard reference for the six-minute-walk test in healthy children aged 7 to 16 years
Albert M. Li et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2007)
The MPS I registry: Design, methodology, and early findings of a global disease registry for monitoring patients with Mucopolysaccharidosis Type I
Gregory M. Pastores et al.
MOLECULAR GENETICS AND METABOLISM (2007)
Fabry disease: Baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry
C. M. Eng et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2007)
A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years
Monica Sifuentes et al.
MOLECULAR GENETICS AND METABOLISM (2007)
Cardiac findings after enzyme replacement therapy for mucopolysaccharidosis type I
Elizabeth A. Braunlin et al.
AMERICAN JOURNAL OF CARDIOLOGY (2006)
Enzyme replacement therapy for mucopolysaccharidosis VI: A Phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study
Paul Harmatz et al.
JOURNAL OF PEDIATRICS (2006)
Cumulative incidence rates of the mucopolysaccharidoses in Germany
F Baehner et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2005)
Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome):: Results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase
P Harmatz et al.
PEDIATRICS (2005)
Threshold effect of urinary glycosaminoglycans and the walk test as indicators of disease progression in a survey of subjects with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome)
SJ Swiedler et al.
AMERICAN JOURNAL OF MEDICAL GENETICS PART A (2005)
Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome)
P Harmatz et al.
JOURNAL OF PEDIATRICS (2004)
Clinical and biochemical study of 28 patients with mucopolysaccharidosis type VI
ACMM Azevedo et al.
CLINICAL GENETICS (2004)
The status of hematopoietic stem cell transplantation in lysosomal storage disease
JJ Malatack et al.
PEDIATRIC NEUROLOGY (2003)
The Gaucher registry -: Demographics and disease characteristics of 1698 patients with Gaucher disease
J Charrow et al.
ARCHIVES OF INTERNAL MEDICINE (2000)
Share Paper
